What Eli Lilly's Quarter ended Sep 30, 2026 10-Q says: 4 signals
Eli Lilly filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses acquisition completed, compliance burden and debt refinancing.
Get Eli Lilly's live signals in Claude or ChatGPT, or by API
What changed at Eli Lilly this week? Use Autobound signals for lilly.com.- Filed
- Oct 29, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 15
Source: Autobound Signal API · 114 signals tracked for Eli Lilly · updated
10-Q · latest 10
What Eli Lilly's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 4 signals
Eli Lilly issued $9.0 billion in long-term debt in May 2026
In May 2026, the company issued $9.0 billion of long-term debt to repay commercial paper and fund upfront cash consideration for acquisitions of Centessa and Kelonia.
$9B
issuance of long-term debt
Eli Lilly acquired Merida in October 2026 for up to $2.9 billion
Eli Lilly completed the acquisition of Merida in October 2026 for an aggregate consideration of up to $2.9 billion, including upfront and milestone payments.
$2.9B
aggregate consideration to acquire Merida
Eli Lilly launched Foundayo (orforglipron) for obesity treatment in the U.S.
Eli Lilly launched Foundayo in the U.S. in the second quarter of 2026 and submitted it to the FDA for type 2 diabetes.
HHS selected Trulicity and Verzenio in January 2026 for government-set pricing
Under the Inflation Reduction Act of 2022, HHS selected Jardiance effective 2026, and selected Trulicity and Verzenio in January 2026 to be effective in 2028.
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 7 signals
Eli Lilly Paid $13.3 Billion for Five Acquisitions and $2.0 Billion in July
Eli Lilly paid $13.3 billion in 2026 for business development activity driven by acquisitions of Centessa, Kelonia, Orna, Ventyx, and Ajax, plus an additional $2.0 billion in July 2026 for infectious disease assets.
$13.3B
paid in 2026 related to business development activity, primarily driven by acquisitions of Centessa, Kelonia, Orna, Ventyx, and Ajax
Eli Lilly issues $9.0 billion in long-term debt in May 2026
In May 2026, Lilly issued $9.0 billion of long-term debt to fund general corporate purposes, repay commercial paper, and finance upfront consideration and fees for the acquisitions of Centessa and Kelonia.
$9B
long-term debt issuance
Eli Lilly Signed Agreement to Acquire AtaiBeckley Inc. for Approximately $2.8 Billion
Eli Lilly entered into an agreement to acquire AtaiBeckley Inc.
$2.8B
potential amount payable at closing for pending acquisition of AtaiBeckley Inc.
Eli Lilly Launched Foundayo (orforglipron) in U.S. Following FDA Approval for Obesity
Eli Lilly launched Foundayo (orforglipron) in the U.S.
Eli Lilly records $703 million in restructuring and special charges in Q2 2026
The company recorded $703 million for Q2 2026 and $982 million for the first six months of 2026 in asset impairment, restructuring, and other special charges.
Eli Lilly experiences 13% realized price declines consolidated in Q2 2026
Consolidated realized prices declined 13% for the three and six months ended June 30, 2026, including a 36% decline outside the U.S.
-13%
consolidated price change for the three months ended June 30, 2026
Earlier 10-Q filings
- 10-Q · Quarter ended Mar 31, 2026Filed · 4 signalsSEC EDGAR
Showing 10 of 15 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Eli Lilly earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Full year 2026 revenue guidance raised to $91B-$92BFull year revenue outlook was raised to between $91 billion and $92 billion, driven by rapid uptake of the Medicare GLP-1 bridge program and robust international Mounjaro demand. Non-GAAP EPS expectations increased to $35 to $36, reflecting an operational increase of $4.07 per share at the midpoint prior to acquired IPR&D adjustments. The substantial top-line upgrade signals strong commercial... | |
| Revenue grew 39% driven by Mounjaro and ZepboundWorldwide revenue increased nearly $7 billion or 39% compared to Q3 2025, driven by strong incretin volume and therapeutic area momentum. Gross margin expanded 80 basis points to 84.4%, while non-GAAP performance margin reached 54.2%. Strong revenue expansion provides significant budget flexibility for outward operational and commercial investments. | |
| Broke ground on $11.5B manufacturing facilities in Texas and VirginiaThe company broke ground on two large-scale manufacturing facilities, comprising a $6.5 billion site in Houston, Texas, and a $5.0 billion site in Richmond, Virginia. These major capital commitments aim to support long-term production and global supply chain expansion for incretin products. Construction and automation rollouts create immediate procurement opportunities for engineering... | |
| Completed acquisitions of AtaiBeckley and Merida BiosciencesThe company completed acquisitions of AtaiBeckley, adding neuroplasticens for mental health conditions, and Merida Biosciences, adding MR511 for precision immunology in Graves' disease. These business development transactions expand clinical pipelines across neuroscience and immunology. The onboarding of acquired clinical teams triggers standard vendor evaluations and laboratory informatics... | |
| Launched Foundayo in UK, Mexico, Saudi Arabia and UAEInternational commercial rollout of oral obesity drug Foundayo advanced with launches in the UK, Saudi Arabia, Mexico, and the UAE, alongside preparations for 40 additional international markets in 2027. Expansion initially targets cash-pay and chronic weight management markets while reimbursement discussions progress. Geographic rollouts require localized distribution, compliance, and... | |
| R&D spending increased 23% and SG&A rose 14%R&D expenses increased 23% in Q3 driven by clinical investments across early- and late-stage pipeline assets and newly acquired molecules. Marketing, selling, and administrative expenses rose 14% to support promotional and launch activities for current and upcoming products. Increased spending lines indicate active vendor engagement across clinical trial services and commercial sales software. |
Signal API · MCP
Track Eli Lilly with the Signal API
One POST /v1/companies/enrich call with lilly.com returns Eli Lilly 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"lilly.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Eli Lilly 10-Q
When did Eli Lilly file its latest 10-Q?
What did Eli Lilly disclose in its latest 10-Q?
What did Eli Lilly say on its recent earnings calls?
Where can I read Eli Lilly's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .